180 LIFE SCIENCES CORP (ATNF)

Company Profile

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California and currently employs 4 full-time employees. The company went IPO on 2017-06-07. The firm is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The firm has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). The company is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is undertaking preclinical research and development activities for the SCA platform.

Company Info

180 LIFE SCIENCES CORP

3000 El Camino Real, Bldg 4, Ste 200

Palo Alto CALIFORNIA 10019

P: 16505070669

CEO: James N. Woody

Employees: 4

Website: https://180lifesciences.com/